- Chronic oxidative stress and inflammation are associated with various conditions, including cosmetic applications such as over-pigmentation disorders and skin whitening. Oxidative stress activates inflammatory/apoptotic pathways, leading to the release of pro-inflammatory cytokines, chemokines, and immune cell infiltration, exacerbating tissue damage and disease progression.
- There is an unmet need to treat oxidative-induced inflammatory damages like skin disorders, atopic dermatitis, over pigmentations, eye disorders (AMD, retinitis pigmentosa, cataract), epilepsy, Parkinson’s disease, and other inflammatory/oxidative-related disorders.
- Thioredoxin 1 (Trx1) is an antioxidant protein that plays a crucial role in maintaining redox homeostasis and protecting cells from oxidative stress. Trx-mimetic (TXM) peptides are synthetic ultra-small peptides designed to mimic the function of the natural antioxidant protein Trx1. The present technology is a novel proteolysis-resistant Trx-mimetic peptides that might become very effective by displaying a prolonged in vivo activity.
A novel strategy for treating oxidative-induced inflammatory damage with proteolysis-resistant Trx-mimetic peptides. These non-toxic small molecules have therapeutic and anti-inflammatory/anti-oxidative properties and can act at a well-defined molecular mechanism of action for various indications.
- Combination of antioxidative/anti-inflammatory activities with tyrosinase inhibition using novel Trx mimetics that are more resistant to hydrolysis by proteases.
- Unique structure that prolongs intracellular activity by increasing the biological lifetime and bioavailability.
- Use of non-toxic small peptides harboring 3 or 4 amino acids, which mimic the active site of Trx.
- Use of peptides/antioxidants that are selectively targeted to intracellular substrates of Trx (like the MAPKs), which exhibit a selective mode of action and indicate a well-defined molecular mechanism.
- Novel treatment for various indications such as over-pigmentation disorders, skin whitening, premature cell death, aging, epilepsy, viral infection, and macular degeneration.
We are seeking collaboration with pharmaceutical or cosmetic companies, interested in novel treatments for cosmetic conditions such as over-pigmentation disorders and skin whitening.